Chemoradiotherapy with high-dose cisplatin compared to weekly cisplatin for locally advanced head and neck squamous cell carcinoma
- Resource Type
- Authors
- Kathryn M. Greven; Thomas Lycan; Bart Frizzell; Ryan T. Hughes; R.F. Shenker; Beverly J. Levine; Mercedes Porosnicu
- Source
- J Med Imaging Radiat Oncol
- Subject
- Oncology
medicine.medical_specialty
medicine.medical_treatment
Antineoplastic Agents
Article
Internal medicine
medicine
Humans
Radiology, Nuclear Medicine and imaging
Stage (cooking)
Retrospective Studies
Cisplatin
Chemotherapy
Performance status
business.industry
Squamous Cell Carcinoma of Head and Neck
Head and neck cancer
Chemoradiotherapy
medicine.disease
Chemotherapy regimen
Head and neck squamous-cell carcinoma
Head and Neck Neoplasms
Carcinoma, Squamous Cell
business
medicine.drug
- Language
- English
INTRODUCTION Concurrent chemoradiotherapy (CRT) using high-dose cisplatin (HDC) is standard for patients with locally advanced head and neck squamous cell carcinoma (HNSCC); weekly cisplatin (WC) is an alternative. We aim to compare retrospectively the survival and disease control outcomes between these regimens in our institutional experience. METHODS Patients with stage III-IV HNSCC treated with definitive or postoperative CRT between 2012 and 2018 were identified. Patients were stratified by intent-to-treat CRT. Overall survival (OS) and disease-free survival (DFS) were generated and multivariable Cox models were performed. RESULTS 193 patients were treated with concurrent HDC (n = 69), WC at 40 mg/m2 (WC40, n = 88) or WC at